1,721,172 research outputs found
Rischio cardiovascolare nei pazienti affetti da malattie infiammatorie croniche: valutazione della relazione tra meccanismi immunologici, profilo metabolico e stile di vita
No full textCardiovascular disease (CVD) is the most frequent cause of death worldwide and well established, traditional risk factors for CVD comprise age, sex, race, hypertension, diabetes, smoking, and hyperlipidaemia, all of which are included in various prediction models. However, over the past 20 years several non-traditional risk factors, such as chronic inflammation, have emerged as amplifiers of CV risk. This notion opened a new scenario putting forward the hypothesis that individuals with chronic inflammatory diseases may display a higher CV risk that could not be explained in full by traditional CV risk factors. The majority of data regarding CV risk and CV diseases in rheumatoid arthritis (RA) and spondyloartritis (SpA) are mainly derived from studies in patients with established disease while data in early phases are less. On this basis the aims of our study were: i. to assess the CV burden, in patients with RA and SpA at the time of disease diagnosis; ii. to explore the burden of metabolic-associated fatty liver disease (MASLD) in patients with RA and SpA at the time of disease diagnosis; iii. to identify possible associations between the CV scenario and disease specific variables. To achieve these aims, we designed a study including a retrospective part exploring the full RA e SpA cohort referring at our Center and a cross-sectional part assessing newly diagnosed patients. Our study demonstrated that while patients with RA seem to develop a cumulative CV burden from the disease onset and during the disease course, patients with SpA already display a consistent CV history with CV events occurring years before SpA diagnosis. Furthermore, we identified differences related to gender within the different diseases accounting for a different risk of CV events. Finally, by assessing arterial characteristics and function in patients at the time of SpA or RA diagnosis, it emerged that while arterial stiffness seems within the normal range, endothelial impairment is already present compared to normal individuals. In conclusion, CV risk assessment in patients with RA and SpA should be thoroughly performed from the time of disease diagnosis and using not only a clinical assessment but also investigational procedures to investigate arterial stiffness and subclinical atherosclerosis
Type IB and type III endoleak 8 years after endovascular aneurysm repair
No full text[No abstract available
Beneficial Cardiovascular Effects of Low-dose Glucocorticoid Therapy in Inflammatory Rheumatic Diseases
No full textCardiovascular Risk in Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Disorders: a Suggested Model of Preventive Strategy.
No full textEarly and mid-term outcomes of a novel endovascular aneurysm sealing (EVAS) system in patients with infrarenal abdominal aortic aneurysms
No full textAbstract:
Background: Endovascular aneurysm sealing (EV AS) using the Nell ix system is a promising technology for Abdominal Aortic Aneurysm (AAA) treatment. Long-term data is unavailable regarding the potential modifications of the EndoBags and their content, and the polymer behavior over time. We present our initial clinical experience with this sac anchoring endoprosthesis in 24 patients with a maximum 12 months follow-up.
Methods and Results: From December 2013 to March 2015, 24 patients with an infrarenal AAA were treated with the NellixTM System. Computed Tomography Angiography (CTA) scan control was performed at 30 days, and follow-up Magnetic Resonance Angiography (MRA) and ultrasounds were performed at 30 days, 6 and 12 months. Median and peak systolic velocities in the suprarenal aorta were measured preoperatively and during follow-up using phase contrast sequences and Argus (Siemens, Erlangen, Germany) software of the MRA. We achieved 100% technical success, 0% aneurysm-related mortality and 0% endoleaks. One patient (4%) experienced early acute thrombosis ofa single Nellix stent, successfully treated with thrombolysis. Sac shrinkage occurred in 80% of cases with 12 months follow-up.
Conclusions: Our preliminary clinical experience is promising, with I 00% early technical success and satisfactory sealing of the aneurysm sac. Post-procedural controls during I-year- follow-up revealed no morphologic changes of the aneurysm wall, stable device and endobag position, and gradual dissolution of the air initially trapped within the EndoBags. Aneurysmal sac shrinkage occurs and probably is due to the remodeling of the thrombus around the
Endo Bags and the dissipation of the air bubbles into the Endo Bags
- …
